Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShort-Term Debt repayments
Ratios

bioAffinity Technologies (BIAF) EBIAT (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed EBIAT for 4 consecutive years, with -$5.1 million as the latest value for Q3 2025.

  • On a quarterly basis, EBIAT fell 152.45% to -$5.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$14.7 million, a 74.51% decrease, with the full-year FY2024 number at -$9.0 million, down 13.89% from a year prior.
  • EBIAT was -$5.1 million for Q3 2025 at bioAffinity Technologies, down from -$4.1 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of -$88052.0 in Q2 2022 to a low of -$5.1 million in Q3 2025.
  • A 4-year average of -$2.5 million and a median of -$2.1 million in 2024 define the central range for EBIAT.
  • Biggest YoY gain for EBIAT was 53.43% in 2023; the steepest drop was 1876.3% in 2023.
  • bioAffinity Technologies' EBIAT stood at -$1.7 million in 2022, then plummeted by 41.72% to -$2.4 million in 2023, then dropped by 25.02% to -$3.0 million in 2024, then crashed by 70.25% to -$5.1 million in 2025.
  • Per Business Quant, the three most recent readings for BIAF's EBIAT are -$5.1 million (Q3 2025), -$4.1 million (Q2 2025), and -$2.7 million (Q1 2025).